Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its...
Direct Biologics, a market-leading innovator and cGMP manufacturer of regenerative biologic products, announced today that it has received FDA approval to initiate a Phase I/II trial under an...
As intensive care units across the country fill to capacity, hospital beds are in dangerously short supply, and deaths from COVID-19 continue to spike, doctors from medical centers coast to coast are ...
Direct Biologics, LLC announced the launch today of EXIT COVID-19, their Phase II, multi-center clinical trial examining the use of ExoFlo™ extracellular vesicles to treat COVID-19 associated acute...
Direct Biologics, LLC announces a rapid acceleration of the investigational use of ExoFlo™ for treatment of COVID-19 as new mechanisms of SARS-CoV-2 have been revealed. Published in Lung Cellular and ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.